Who
Matthew Paul Kowalsky
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Enanta Pharmaceuticals; Chief of Staff and CLO, Sigilon Therapeutics; VP, Legal and Secretary, Protara Therapeutics.
In numbers
- Trades disclosed
- 18
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 30 Jun 2017
- Last trade
- 12 Feb 2026
- Last filed
- 13 Feb 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,318 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —4,175 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $27K1,902 at $14.25 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,318 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —4,175 at $0.00 | filing |
| 12 Feb 2026filed 13 Feb 2026 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $27K1,902 at $14.25 | filing |
| 25 Nov 2025filed 26 Nov 2025 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 27 Nov 2024filed 27 Nov 2024 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 29 Apr 2024filed 1 May 2024 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 11 Aug 2023filed 11 Aug 2023 | Sigilon Therapeuticsoption or derivative | SEC FORM 4 Code D | $9,51812,690 at $0.75 | filing |
| 11 Aug 2023filed 11 Aug 2023 | Sigilon Therapeutics | SEC FORM 4 Code D | —1,925 | filing |
| 28 Feb 2023filed 1 Mar 2023 | Sigilon Therapeuticsoption or derivative | SEC FORM 4 Code A | —165,000 at $0.00 | filing |
| 18 Jan 2019filed 23 Jan 2019 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 31 Dec 2018filed 3 Jan 2019 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code A | $4,7252,448 at $1.93 | filing |
| 29 Jun 2018filed 3 Jul 2018 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code A | $16K10,000 at $1.62 | filing |
| 17 Jan 2018filed 18 Jan 2018 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 29 Dec 2017filed 3 Jan 2018 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code A | $5,1143,934 at $1.30 | filing |
| 30 Jun 2017filed 5 Jul 2017 | TARA Protara TherapeuticsBiotechnology | SEC FORM 4 Code A | $13K10,000 at $1.30 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.